Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01838395 · ClinicalTrials.gov registry record · Phase 2
Phase IIa Study Evaluating Safety and Efficacy of BL-8040 in Relapsed/Refractory AML Patients
A Phase 2 study, sponsored by BioLineRx.
- Completed
- Registry status
- Phase 2
- Development phase
- 42
- Enrollment target
NCT01838395: Completed Phase 2 study, sponsored by BioLineRx.
NCT01838395 is a Phase 2 study that has completed, run by BioLineRx. The registered enrollment target is 42 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01838395, a Phase 2 study, has completed, sponsored by BioLineRx.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 42 participants
- Enrollment target
Study Summary
A study is designed to assess if BL-8040 in combination with cytarabine (Ara-C) can help controlling the disease in patients with Acute Myeloid Leukemia (AML) that have relapsed or did not respond adequately to previous treatment. The safety of the study drug combination will also be studied.
Interventions
- DRUG Ara-C
- DRUG BL-8040
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Start Date | 2013-04 |
| Est. Completion | 2023-07-20 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01838395
The ClinicalTrials.gov registry entry for NCT01838395 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 42 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is BioLineRx, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Ara-C is the first listed.
NCT01838395 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01838395 about?
NCT01838395 is a clinical study titled "Phase IIa Study Evaluating Safety and Efficacy of BL-8040 in Relapsed/Refractory AML Patients". A study is designed to assess if BL-8040 in combination with cytarabine (Ara-C) can help controlling the disease in patients with Acute Myeloid Leukemia (AML) that have relapsed or did not respond adequately to previous treatment. The safety of the study drug combination will also be studied.
What is the current status of trial NCT01838395?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 42 participants. The study started on 2013-04. Estimated completion is 2023-07-20.
What interventions are being tested in trial NCT01838395?
The interventions under investigation include: Ara-C (DRUG), BL-8040 (DRUG).
Who is sponsoring clinical trial NCT01838395?
This trial is sponsored by BioLineRx, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.